Microglial Foxo3 shapes dopaminergic vulnerability in Parkinson disease
Baptiste Texier, Sarah Roudaud, Quentin Husson, Morgane Prime, Marie Alma, Lisaydi Dominguez-Coronado, David Frieser, Anne-Louise Le Dorze, Margot Zahm, Anne-Laure Iscache, Daniel Alvarez‐Fischer, Anne S. Dejean, Bernard Klonjkowski, Stéphane Hunot, Séverine Fruchon, Marion Szelechowski
This study identifies Foxo3 as a key regulator of dopaminergic vulnerability through microglial mechanisms, showing that baseline microglial state, rather than acute transcriptional responses, determines neurodegeneration in Parkinson's disease.
bioRxiv · May 23, 2026 · PreprintNeuroscience